Julie L. Boerner

3.4k total citations
63 papers, 2.4k citations indexed

About

Julie L. Boerner is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Julie L. Boerner has authored 63 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 30 papers in Molecular Biology and 15 papers in Cancer Research. Recurrent topics in Julie L. Boerner's work include HER2/EGFR in Cancer Research (18 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Julie L. Boerner is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Julie L. Boerner collaborates with scholars based in United States, Italy and France. Julie L. Boerner's co-authors include Kelly L. Mueller, Sarah J. Parsons, Corinne M. Silva, Stephen P. Ethier, Natacha Bohin, Mary E. Irwin, Jacqueline S. Biscardi, Yubin Ge, Julie Madden and Karin List and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Nature Communications.

In The Last Decade

Julie L. Boerner

62 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie L. Boerner United States	27	1.3k	1.2k	438	414	214	63	2.4k
John R. Hawse United States	36	1.9k 1.4×	823 0.7×	575 1.3×	332 0.8×	113 0.5×	113	3.3k
Somaira Nowsheen United States	37	2.1k 1.6×	1.3k 1.1×	480 1.1×	357 0.9×	228 1.1×	74	3.2k
Hua Guo United States	24	1.3k 0.9×	840 0.7×	315 0.7×	273 0.7×	126 0.6×	69	2.3k
Eduardo Farias United States	29	1.4k 1.1×	774 0.7×	618 1.4×	212 0.5×	116 0.5×	67	2.7k
James G. Jackson United States	36	2.4k 1.8×	1.5k 1.2×	818 1.9×	250 0.6×	184 0.9×	70	3.8k
Rossano Lattanzio Italy	29	1.3k 0.9×	959 0.8×	436 1.0×	290 0.7×	122 0.6×	83	2.7k
Susan Minton United States	22	1.4k 1.1×	1.4k 1.2×	563 1.3×	351 0.8×	90 0.4×	41	2.9k
Marja T. Nevalainen United States	37	1.8k 1.3×	1.7k 1.4×	876 2.0×	1.0k 2.4×	91 0.4×	77	3.7k
Janete M. Cerutti Brazil	32	1.3k 1.0×	687 0.6×	454 1.0×	210 0.5×	414 1.9×	102	3.7k
Luca Messerini Italy	35	1.0k 0.8×	1.1k 1.0×	467 1.1×	729 1.8×	350 1.6×	113	3.7k

Countries citing papers authored by Julie L. Boerner

Since Specialization

Citations

This map shows the geographic impact of Julie L. Boerner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie L. Boerner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie L. Boerner more than expected).

Fields of papers citing papers by Julie L. Boerner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie L. Boerner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie L. Boerner. The network helps show where Julie L. Boerner may publish in the future.

Co-authorship network of co-authors of Julie L. Boerner

This figure shows the co-authorship network connecting the top 25 collaborators of Julie L. Boerner. A scholar is included among the top collaborators of Julie L. Boerner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie L. Boerner. Julie L. Boerner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aly, Mai, Tariq Kewan, Waled Bahaj, et al.. (2025). Comprehensive Age-Stratified Impact of NPM1 Mutation in Acute Myeloid Leukemia: A Real-World Experience. Cancers. 17(6). 1020–1020. 2 indexed citations

Brown, Michael C., David Boczkowski, Nadeem A. Sheikh, et al.. (2024). Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T. Cancer Research Communications. 4(10). 2724–2733. 3 indexed citations

Boerner, Julie L., et al.. (2024). The role of epithelial-mesenchymal transition markers in invasive breast cancer among patients of Arab descent.. Journal of Clinical Oncology. 42(16_suppl). e13166–e13166. 1 indexed citations

Heath, Elisabeth I., Archana Thakur, Wei Chen, et al.. (2024). Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer. Cancer Research Communications. 4(7). 1715–1725. 3 indexed citations

Trendowski, Matthew R., Donovan Watza, Christine M. Lusk, et al.. (2024). Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non–Small Cell Lung Cancer. Cancer Epidemiology Biomarkers & Prevention. 33(9). 1220–1228. 3 indexed citations

Ruterbusch, Julie J., Wei Chen, Julie L. Boerner, et al.. (2024). Multiplicity of benign breast disease lesions and breast cancer risk in African American women. Frontiers in Oncology. 14. 1410819–1410819. 1 indexed citations

Heath, Elisabeth I., et al.. (2022). Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men. The Prostate. 82(6). 666–675. 1 indexed citations

Brock, Ethan J., Julie L. Boerner, Quan-Wen Li, et al.. (2021). Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma. PLoS ONE. 16(5). e0252314–e0252314. 5 indexed citations

Bao, Bin, et al.. (2020). Role of TET1 and 5hmC in an Obesity-Linked Pathway Driving Cancer Stem Cells in Triple-Negative Breast Cancer. Molecular Cancer Research. 18(12). 1803–1814. 31 indexed citations

10.

Sanai, Nader, Jing Li, Julie L. Boerner, et al.. (2018). Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients. Clinical Cancer Research. 24(16). 3820–3828. 61 indexed citations

11.

Vaishampayan, Ulka N., Izabela Podgorski, Lance K. Heilbrun, et al.. (2018). Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clinical Cancer Research. 25(2). 652–662. 3 indexed citations

12.

Gadgeel, Shirish M., Nathan A. Pennell, Mary J. Fidler, et al.. (2018). Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. 13(9). 1393–1399. 155 indexed citations

13.

Shah, Seema, Ethan J. Brock, Kyungmin Ji, et al.. (2018). Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia. 20(9). 951–963. 21 indexed citations

14.

Tanabe, Lauren M., Fausto A. Varela, Andrew S. Murray, et al.. (2015). Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling. Nature Communications. 6(1). 6776–6776. 50 indexed citations

15.

Mueller, Kelly, et al.. (2013). Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells. Journal of Surgical Research. 185(1). 231–239. 38 indexed citations

16.

Boerner, Julie L., et al.. (2011). Strong expression association between matriptase and its substrate prostasin in breast cancer. Journal of Cellular Physiology. 227(4). 1604–1609. 31 indexed citations

17.

Boerner, Julie L., Jacqueline S. Biscardi, Corinne M. Silva, & Sarah J. Parsons. (2005). The role of EGF and transactivating agonists in EGFR/c-Src synergy. Cancer Research. 65. 1238–1238. 1 indexed citations

18.

Boerner, Julie L., et al.. (2004). Phosphorylation of Y845 on the Epidermal Growth Factor Receptor Mediates Binding to the Mitochondrial Protein Cytochrome c Oxidase Subunit II. Molecular and Cellular Biology. 24(16). 7059–7071. 164 indexed citations

19.

Rich, Tyvin A., Pasquale F. Innominato, Marie‐Christine Mormont, et al.. (2004). Performance status, global quality of life, fatigue, and appetite loss are correlated with serum TGFa and IL-6 in patients with metastatic colorectal cancer (MCC). Journal of Clinical Oncology. 22(14_suppl). 8024–8024. 2 indexed citations

20.

Boerner, Julie L., Andrew J. Danielsen, Courtney A. Lovejoy, et al.. (2003). Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis. Oncogene. 22(43). 6679–6689. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact